PMC:3574749 / 35519-36768 JSONTXT

{"project":"2_test","denotations":[{"id":"23431469-20471864-54707437","span":{"begin":166,"end":168},"obj":"20471864"},{"id":"23431469-21598031-54707438","span":{"begin":370,"end":373},"obj":"21598031"},{"id":"23431469-21331979-54707439","span":{"begin":444,"end":447},"obj":"21331979"},{"id":"23431469-16318457-54707440","span":{"begin":729,"end":732},"obj":"16318457"},{"id":"23431469-22142976-54707441","span":{"begin":1081,"end":1084},"obj":"22142976"}],"text":"4.3. Treating Depression and Anxiety\nThe prevalence of depression and anxiety across each decade of life for adults with HIV hovers around 40% and 20%, respectively [94]. As already mentioned (see Cortisol, Negative Affect, and Substance Abuse section), there is a strong (and possible causal) connection between negative mood and cognition in this clinical population [143]. In fact, in a sample of 107 adults with HIV, Thames and colleagues [144] found that those who experienced elevated levels of depression reported more cognitive problems. Thus, treating psychiatric comorbidities may also be important for protecting and improving cognitive functioning [145]; in fact, several studies show this. Claypoole and colleagues [146] found that in a sample of 78 adults with HIV suffering from depression and treated with antidepressants for 12 weeks reported significantly fewer cognitive problems and improved on objective measures of cognitive functioning. Given the strong connection between negative mood and cognitive functioning via the hypothalamic-pituitary-adrenal axis [107], treating psychiatric comorbidities such as depression and anxiety should be considered as a potential treatment of cognitive deficits in this clinical population."}

{"project":"NEUROSES","denotations":[{"id":"T396","span":{"begin":55,"end":65},"obj":"PM3425"},{"id":"T390","span":{"begin":197,"end":205},"obj":"CHEBI_17650"},{"id":"T391","span":{"begin":228,"end":237},"obj":"PATO_0000142"},{"id":"T392","span":{"begin":265,"end":271},"obj":"PATO_0001716"},{"id":"T393","span":{"begin":970,"end":976},"obj":"PATO_0001716"},{"id":"T394","span":{"begin":482,"end":490},"obj":"PATO_0001688"},{"id":"T395","span":{"begin":822,"end":837},"obj":"CHEBI_35469"},{"id":"T397","span":{"begin":501,"end":511},"obj":"PM3425"},{"id":"T398","span":{"begin":794,"end":804},"obj":"PM3425"},{"id":"T399","span":{"begin":1130,"end":1140},"obj":"PM3425"},{"id":"T400","span":{"begin":14,"end":24},"obj":"PM3425"},{"id":"T401","span":{"begin":55,"end":65},"obj":"PM3425"},{"id":"T402","span":{"begin":501,"end":511},"obj":"PM3425"},{"id":"T403","span":{"begin":794,"end":804},"obj":"PM3425"},{"id":"T404","span":{"begin":1130,"end":1140},"obj":"PM3425"}],"text":"4.3. Treating Depression and Anxiety\nThe prevalence of depression and anxiety across each decade of life for adults with HIV hovers around 40% and 20%, respectively [94]. As already mentioned (see Cortisol, Negative Affect, and Substance Abuse section), there is a strong (and possible causal) connection between negative mood and cognition in this clinical population [143]. In fact, in a sample of 107 adults with HIV, Thames and colleagues [144] found that those who experienced elevated levels of depression reported more cognitive problems. Thus, treating psychiatric comorbidities may also be important for protecting and improving cognitive functioning [145]; in fact, several studies show this. Claypoole and colleagues [146] found that in a sample of 78 adults with HIV suffering from depression and treated with antidepressants for 12 weeks reported significantly fewer cognitive problems and improved on objective measures of cognitive functioning. Given the strong connection between negative mood and cognitive functioning via the hypothalamic-pituitary-adrenal axis [107], treating psychiatric comorbidities such as depression and anxiety should be considered as a potential treatment of cognitive deficits in this clinical population."}